Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darinaparsin - Solasia Pharma

Next Previous
X
Search
Drug Profile

Darinaparsin - Solasia Pharma

Alternative Names: Darvias; SP-02; SP-02L; Zinapar; ZIO-101

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Texas A&M University; University of Texas M. D. Anderson Cancer Center
  • Developer Nippon Kayaku; Solasia Pharma; ZIOPHARM Oncology
  • Class Amines; Antineoplastics; Arsenicals; Oligopeptides; Pentanoic acids; Small molecules; Sulfides
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Discontinued Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 14 Jun 2024 Phase-II clinical trials in Peripheral T-cell lymphoma in China (IV), prior to June 2024 (Solasia Pharma pipeline, June 2024)
  • 14 Jun 2024 Phase-II clinical trials in Peripheral T-cell lymphoma in Europe (IV), prior to June 2024 (Solasia Pharma pipeline, June 2024)
  • 14 Jun 2024 Solasia Pharma files for regulatory approval for Peripheral T-cell lymphoma in Colombia, prior to June 2024 (Solasia Pharma pipeline, June 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top